ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / JANX / news
HROW (53) SPTX (48) CTY (50) MNKD (56) ⌘ Pro Terminal →

Why JANX Stock slipped -0.06% Today — RQD Quant Desk Flash

$17.46 -0.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $17.42

Janux Therapeutics Inc. (JANX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.07B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on JANX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is JANX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Janux Therapeutics Inc. (NASDAQ: JANX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $17.46 (-0.06% 1D, market cap $1.07B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, JANX ranks #530 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does JANX compare to HROW and SPTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JANX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -13.8%. By comparison, HROW (Harrow Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC 42.9%, cap $1.06B) and SPTX (Seaport Therapeutics Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $1.05B). Among the 5-stock peer group, JANX leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for JANX?
▼

Per JANX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817713), Janux Therapeutics Inc. generated $441.5M in revenue (+59.5% YoY), -$113.6M in net income, and -$83.3M in free cash flow against $1.00B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $17.43 (-0.20%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (6)Whales (8)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.5% Base Target
$37 Bull$16 Base$12 Bear
📬 FREE JANX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JANX)Realized 20D OHLCV Swing Band: ±11%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY JANX SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 23% of 52W Range • RSI-14 at 51.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$17.18+0.1% Next Q
Q2 (-2Q)
32
Grade E$17.20+0.3% Next Q
Q3 (-1Q)
34
Grade E$17.26+1.2% Next Q
Current
37
Grade D-$17.46-8.1% Hist 90D α
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a JANX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While JANX currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($17.58) and Max Pain ($18.33) forces dealer call-delta covering toward $37.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $JANX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “JANX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why JANX Stock slipped -0.06% Today — RQD Quant Desk Flash

Janux Therapeutics Inc. (JANX) slipped -0.06% to $17.46, trading at 23% of its 52-week range ($12.12 – $35.34). Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 23% of its 52-week range ($12.12 – $35.34) with RSI-14 at 51.4 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±11% around $17.46 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live JANX Headlines & Catalysts
CATALYSTYahoo • 6d ago
Ensign Group (ENSG) Beats Q3 Earnings Estimates

Ensign Group (ENSG) delivered earnings and revenue surprises of +4.64% and -0.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JANX)

  • ✓Walkthrough of JANX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
JANX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.08%▲ ASCENDING CHANNEL
2026-11-03O $17.83H $17.83L $17.46C $17.46VOL 540.1K
RES: $23.41SUP: $16.46SMA50: $17.58SMA200: $15.37
$20.82$18.70$16.57$14.45$12.32RES $23.41SUP $16.46$17.462026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JANX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 JANX Butterfly Map → + Track JANX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +59.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on JANX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JANX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JANX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JANX)

Health Care Rank #530 of 1015 ⚔️ HROW vs JANX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JANX vs. HROW, SPTX, CTY, MNKD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Janux Therapeutics Inc. (JANX) ranks #530 by composite RQD confidence (37/100, grade D-) and #349 by equity capitalization ($1.07B). Within this direct 5-issuer industry benchmark cohort, JANX leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. MNKD currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with JANX at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
JANX ACTIVE
Janux Therapeutics Inc.
D- 37/100 — — -13.8% -0.06% $1.07B Benchmark Subject
HROW
Harrow Inc.
D+ 53/100 — 75.1% 42.9% -0.14% $1.06B /hrow-vs-janx →
SPTX
Seaport Therapeutics Inc.
D 48/100 — — — +2.09% $1.05B /sptx-vs-janx →
CTY
City Therapeutics Inc.
D 50/100 — — — +0.82% $1.04B /cty-vs-janx →
MNKD
MannKind Corporation
D+ 56/100 — 92.3% 54.5% +4.29% $1.13B /mnkd-vs-janx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001817713 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Janux Therapeutics Inc. (JANX) reported GAAP revenue of $441.5M (+59.5% vs. FY2024 revenue of $276.8M , and +116.0% cumulative change since FY2023) , GAAP net income of -$113.6M, operating cash flow of -$82.2M, and free cash flow of -$83.3M (-88.5% YoY). On the balance sheet, JANX closed FY2025 with $1.00B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $441.5M -$113.6M -$82.2M -$83.3M $1.00B —
FY2024 (FY) 2024-12-31 $276.8M -$69.0M -$43.8M -$44.2M $1.06B —
FY2023 (FY) 2023-12-31 $204.3M -$58.3M -$50.6M -$50.6M — —

3. JANX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JANX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Janux Therapeutics Inc. (NASDAQ: JANX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $17.46 (-0.06% 1D, market cap $1.07B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, JANX ranks #530 in composite RQD confidence.

How does JANX compare to HROW and SPTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JANX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -13.8%. By comparison, HROW (Harrow Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC 42.9%, cap $1.06B) and SPTX (Seaport Therapeutics Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $1.05B). Among the 5-stock peer group, JANX leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for JANX?

Per JANX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817713), Janux Therapeutics Inc. generated $441.5M in revenue (+59.5% YoY), -$113.6M in net income, and -$83.3M in free cash flow against $1.00B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is JANX trading relative to its 50-day, 200-day, and 52-week technical levels?

JANX last traded at $17.46 (-0.06% on volume of 412,785 shares), positioning the stock -0.68% below its 50-day simple moving average ($17.58) and +13.60% above its 200-day simple moving average ($15.37). Across its 52-week range of $12.12 to $35.34, JANX sits at the 23.0% percentile with a 14-day RSI of 51.4 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($15.54 to $19.38).

Direct Sub-Reports: JANX RQD Cockpit JANX 12M Forecast JANX Earnings & Move JANX Dividends & DRIP JANX Insiders & 13F JANX Whale Options JANX Profit Sankey JANX News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

JANX — Janux Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Janux Therapeutics Inc. (JANX) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $17.46 (-0.06% 1D, market capitalization $1.07B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -13.8%, gross margin of —, operating margin of —, and free cash flow yield of -7.64%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Janux Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It carries a market capitalization of $1.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Janux Therapeutics Inc. (JANX) reported $441.5M in annual revenue (up from $276.8M in FY2024, +59.5% YoY) and -$113.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($204.3M revenue, -$58.3M net income) through FY2025, JANX scaled operating cash flow to -$82.2M and free cash flow to -$83.3M, backed by $1.00B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.64% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $12.12 – $35.34 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), JANX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can JANX sustain or expand its — operating margin and -13.8% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $441.5M and free cash flow of -$83.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is JANX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

JANX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Janux Therapeutics Inc. (JANX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to JANX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

JANX Bull vs. Bear Conversation Board — What's Your Call at $17.46?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON JANX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on JANX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $22.71 (+30.0%)
📌 Pinned Debate

The whale 13F flow pillar, at 12 of 20, is the rating's strongest component, indicating institutional accumulation.

Here is why I am bullish on JANX here at $17.47: The whale 13F flow pillar, at 12 of 20, is the rating's strongest component, indicating institutional accumulation.. Compare JANX's 0.0% operating margin and -13.8% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $16.60 are getting bought.

SectorRotator 🐂 BULL

@QuantViper Agree on the RQD 37/100 quality, though with 1.0 beta I'm scaling in with half-size at $17.47 and keeping dry powder in case we test $16.25.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $13.98 (-20.0%)
Spot @ $17.47

Cash fell from $430.6M in FY 2024 to $52.3M in FY 2025 while FCF stayed negative at -$83.3M with zero revenue.

Cash fell from $430.6M in FY 2024 to $52.3M in FY 2025 while FCF stayed negative at -$83.3M with zero revenue.. Look at the math on JANX: paying current EV/EBITDA multiples for -13.8% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $15.37 before getting long.

LIVE TAPE